Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...

What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Gone are the days when Americans would criticize eggs for bad cholesterol. The FDA has put its stamp of approval for kids to ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.